184 related articles for article (PubMed ID: 38261736)
1. Therapeutic strategies and predictive models for Xp11.2 translocation/TFE3 gene fusion renal cell carcinoma in adults based on data of two Chinese medical centers.
Yang Y; Zhao C; Wang Z; Liu F; Zhao M; Yang H; Chen J; Chen X; Shi M; Jiang D; Luo X; Duan Y; Bai Y
Aging (Albany NY); 2024 Jan; 16(2):1696-1711. PubMed ID: 38261736
[TBL] [Abstract][Full Text] [Related]
2. The incidence of renal cell carcinoma associated with Xp11.2 translocation/TFE3 gene fusion in Saudi adult patients with renal cancer: a retrospective tissue microarray analysis.
Al-Maghrabi J; Mufti S; Gomaa W
Pol J Pathol; 2018; 69(4):376-383. PubMed ID: 30786687
[TBL] [Abstract][Full Text] [Related]
3. Contrast-enhanced ultrasound findings of adult renal cell carcinoma associated with Xp11.2 translocation/TFE3 gene fusion: comparison with clear cell renal cell carcinoma and papillary renal cell carcinoma.
Wei S; Tian F; Xia Q; Huang P; Zhang Y; Xia Z; Wu M; Yang B
Cancer Imaging; 2019 Dec; 20(1):1. PubMed ID: 31892340
[TBL] [Abstract][Full Text] [Related]
4. Xp11.2 translocation renal neoplasm with features of TFE3 rearrangement associated renal cell carcinoma and Xp11 translocation renal mesenchymal tumor with melanocytic differentiation harboring NONO-TFE3 fusion gene.
Yu W; Wang Y; Rao Q; Jiang Y; Zhang W; Li Y
Pathol Res Pract; 2019 Sep; 215(9):152521. PubMed ID: 31277953
[TBL] [Abstract][Full Text] [Related]
5. TFE3 Xp11.2 Translocation Renal Cell Carcinoma Mouse Model Reveals Novel Therapeutic Targets and Identifies GPNMB as a Diagnostic Marker for Human Disease.
Baba M; Furuya M; Motoshima T; Lang M; Funasaki S; Ma W; Sun HW; Hasumi H; Huang Y; Kato I; Kadomatsu T; Satou Y; Morris N; Karim BO; Ileva L; Kalen JD; Wilan Krisna LA; Hasumi Y; Sugiyama A; Kurahashi R; Nishimoto K; Oyama M; Nagashima Y; Kuroda N; Araki K; Eto M; Yao M; Kamba T; Suda T; Oike Y; Schmidt LS; Linehan WM
Mol Cancer Res; 2019 Aug; 17(8):1613-1626. PubMed ID: 31043488
[TBL] [Abstract][Full Text] [Related]
6. TFE3 break-apart FISH has a higher sensitivity for Xp11.2 translocation-associated renal cell carcinoma compared with TFE3 or cathepsin K immunohistochemical staining alone: expanding the morphologic spectrum.
Rao Q; Williamson SR; Zhang S; Eble JN; Grignon DJ; Wang M; Zhou XJ; Huang W; Tan PH; Maclennan GT; Cheng L
Am J Surg Pathol; 2013 Jun; 37(6):804-15. PubMed ID: 23598965
[TBL] [Abstract][Full Text] [Related]
7. TFE3-Fusion Variant Analysis Defines Specific Clinicopathologic Associations Among Xp11 Translocation Cancers.
Argani P; Zhong M; Reuter VE; Fallon JT; Epstein JI; Netto GJ; Antonescu CR
Am J Surg Pathol; 2016 Jun; 40(6):723-37. PubMed ID: 26975036
[TBL] [Abstract][Full Text] [Related]
8. Clinicopathologic, treatment and prognosis study of 46 Xp11.2 translocation/TFE3 gene fusion renal cell carcinomas.
Zhou J; Zhao L; Yang Z; Chen Y; Wu X; Xue W
BMC Urol; 2022 Jul; 22(1):109. PubMed ID: 35850864
[TBL] [Abstract][Full Text] [Related]
9. Renal cell carcinoma associated with transcription factor E3 expression and Xp11.2 translocation: incidence, characteristics, and prognosis.
Klatte T; Streubel B; Wrba F; Remzi M; Krammer B; de Martino M; Waldert M; Marberger M; Susani M; Haitel A
Am J Clin Pathol; 2012 May; 137(5):761-8. PubMed ID: 22523215
[TBL] [Abstract][Full Text] [Related]
10. Targeted agents in metastatic Xp11 translocation/TFE3 gene fusion renal cell carcinoma (RCC): a report from the Juvenile RCC Network.
Malouf GG; Camparo P; Oudard S; Schleiermacher G; Theodore C; Rustine A; Dutcher J; Billemont B; Rixe O; Bompas E; Guillot A; Boccon-Gibod L; Couturier J; MoliniƩ V; Escudier B
Ann Oncol; 2010 Sep; 21(9):1834-1838. PubMed ID: 20154303
[TBL] [Abstract][Full Text] [Related]
11. Molecular cytogenetic analysis for TFE3 rearrangement in Xp11.2 renal cell carcinoma and alveolar soft part sarcoma: validation and clinical experience with 75 cases.
Hodge JC; Pearce KE; Wang X; Wiktor AE; Oliveira AM; Greipp PT
Mod Pathol; 2014 Jan; 27(1):113-27. PubMed ID: 23828314
[TBL] [Abstract][Full Text] [Related]
12. Clinical heterogeneity of Xp11 translocation renal cell carcinoma: impact of fusion subtype, age, and stage.
Ellis CL; Eble JN; Subhawong AP; Martignoni G; Zhong M; Ladanyi M; Epstein JI; Netto GJ; Argani P
Mod Pathol; 2014 Jun; 27(6):875-86. PubMed ID: 24309327
[TBL] [Abstract][Full Text] [Related]
13. Utilization of a TFE3 break-apart FISH assay in a renal tumor consultation service.
Green WM; Yonescu R; Morsberger L; Morris K; Netto GJ; Epstein JI; Illei PB; Allaf M; Ladanyi M; Griffin CA; Argani P
Am J Surg Pathol; 2013 Aug; 37(8):1150-63. PubMed ID: 23715164
[TBL] [Abstract][Full Text] [Related]
14. A case of bilateral renal cell carcinoma associated with long-term dialysis showing false-positive immunoreactivity for TFE3 as Xp11 translocation renal cell carcinoma.
Kurisaki-Arakawa A; Saito T; Takahashi M; Mitani K; Fukumura Y; Nagashima Y; Argani P; Yao T
Int J Clin Exp Pathol; 2013; 6(11):2585-90. PubMed ID: 24228124
[TBL] [Abstract][Full Text] [Related]
15. SFPQ/PSF-TFE3 renal cell carcinoma: a clinicopathologic study emphasizing extended morphology and reviewing the differences between SFPQ-TFE3 RCC and the corresponding mesenchymal neoplasm despite an identical gene fusion.
Wang XT; Xia QY; Ni H; Ye SB; Li R; Wang X; Shi SS; Zhou XJ; Rao Q
Hum Pathol; 2017 May; 63():190-200. PubMed ID: 28315422
[TBL] [Abstract][Full Text] [Related]
16. A novel partner of TFE3 in the Xp11 translocation renal cell carcinoma: clinicopathological analyses and detection of EWSR1-TFE3 fusion.
Fukuda H; Kato I; Furuya M; Tanaka R; Takagi T; Kondo T; Nagashima Y
Virchows Arch; 2019 Mar; 474(3):389-393. PubMed ID: 30552521
[TBL] [Abstract][Full Text] [Related]
17. Xp11 translocation renal cell carcinoma with morphological features mimicking multilocular cystic renal neoplasm of low malignant potential: a series of six cases with molecular analysis.
Song Y; Yin X; Xia Q; Zheng L; Yao J; Zeng H; Nie L; Gong J; Zhou Q; Chen N
J Clin Pathol; 2021 Mar; 74(3):171-176. PubMed ID: 32699116
[TBL] [Abstract][Full Text] [Related]
18. A case of PSF-TFE3 gene fusion in Xp11.2 renal cell carcinoma with melanotic features.
Zhan HQ; Chen H; Wang CF; Zhu XZ
Hum Pathol; 2015 Mar; 46(3):476-81. PubMed ID: 25582502
[TBL] [Abstract][Full Text] [Related]
19. Diagnosis of adults Xp11.2 translocation renal cell carcinoma by immunohistochemistry and FISH assays: clinicopathological data from ethnic Chinese population.
Qu Y; Gu C; Wang H; Chang K; Yang X; Zhou X; Dai B; Zhu Y; Shi G; Zhang H; Ye D
Sci Rep; 2016 Feb; 6():21677. PubMed ID: 26880493
[TBL] [Abstract][Full Text] [Related]
20. TMED6-COG8 is a novel molecular marker of TFE3 translocation renal cell carcinoma.
Xu Y; Rao Q; Xia Q; Shi S; Shi Q; Ma H; Lu Z; Chen H; Zhou X
Int J Clin Exp Pathol; 2015; 8(3):2690-9. PubMed ID: 26045774
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]